There’s a psychedelic revolution on the horizon that could change mental health treatment.
Articles
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
MindMed executes an MOU to access the drug delivery system of Israel-based Nextage Therapeutics.
Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives
NASDAQ-listed Enveric Biosciences is merging with private psychedelics company, Magic Med Industries.
Texas Senate Approves Psychedelics And Marijuana Concentrates Bills
The Texas Senate has approved House-passed bills to reduce criminal penalties for possessing marijuana concentrates and require the state to study the therapeutic potential of psychedelics like psilocybin and MDMA.
Wesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer
Wesana's new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.
Robust Capital Flows Continue For Private Psychedelics Companies
Public psychedelics companies have radically scaled-back capital raising due to low share prices. But institutional investors are still pumping large amounts of cash into private players.
MindMed Announces the Approval of Mescaline Study
Mindmed's drug R&D is broadening to include mescaline, after approval by a Swiss ethics committee of a new mescaline-based study.
Use of hallucinogens linked to risk seeking, emotional dysregulation in youth and college students
Hallucinogens benefit from somewhat greater acceptance than many other hard drugs, no doubt due in part to the fact that classic hallucinogens like LSD tend to be less harmful and are less likely to lead to physical dependence.
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
Cybin's 12th patent application further supports the company's novel molecule development.
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.
Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.
Field Trip appoints a former high-ranking Democrat as a Special Advisor to the company.
Texas Senate Advances Bill To Study Healing Potential Of Psychedelics Like Psilocybin and MDMA
A Texas Senate committee on Wednesday unanimously approved a House-passed bill that would require the state to conduct a study into the therapeutic potential of psychedelics like psilocybin and MDMA.
Montana Adult-Use Cannabis Legalization Bill, HB 701, Officially Signed
Governor Greg Gianforte on Tuesday signed the Montana adult-use cannabis bill that will establish a newly formed recreational marijuana program in the state, months after voters in Big Sky country approved a measure to legalize pot.
Canadians Are Not OK, 83% of Canadians Report One Or More Symptoms of Depression With Many Turning To Substances To Cope With Negative Emotions During COVID-19 Pandemic, According to Field Trip Health's First Annual "State of Mind" Survey
Over 80% of Canadians are showing symptoms of depression related to the COVID-19 pandemic, with over half of Canadians feeling "down, depressed or hopeless".
A single dose of psilocybin has a lasting therapeutic effect on migraine headache, according to a new placebo-controlled study
Scientists have started to investigate whether psilocybin, the primary substance responsible for the psychedelic effects of “magic” mushrooms, could be helpful to those who suffer from migraine headache.